DISCLOSURE OF TRANSFER OF VALUE Reporting Period (year): 2015 Date of publication: Fees for service and consultancy (Art. 21 **Donations and** Contibution to costs of Events (Art. 36 PC, Art. 231 PCC) PCC. Art. 231 PCC) Grants to HCOs (Art. 22 PCC, Art. 231 PCC) TOTAL Unique country **Full Name** Principal Practice Address identifier OPTIONAL OPTIONAL Related expenses Sponsorship agreed in the fee for agreements witth service or consultancy Travel & Registration Fees contract, including HCOs/ third parties Fees Accommodation appointed by HCOs to travel & accomodation manage an Event relevant to the contract INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities consultation only, as appropriate) (Art. 272 PCC) Alexandre Campanelli Switzerland N/A N/A 1'000 00 1000 Genf Av. De la Roseraie 76a 0 N/A Eugen Hübscher Biel Switzerland Dufourstr. 17 N/A 0 0 700.00 0 700 N/A N/A 436.20 1'400.00 Basel Switzerland 0 0 1836.20 Jan Izakovic Gempenstr. 2a Christoph Schänzle Olten Louis Giroudstr. 20 N/A N/A 0 0 1'200.00 0 1200 Switzerland N/A N/A 1'000.00 Peter Schiller Liestal Switzerland Ω Ω 1000 Mühlegasse 3 N/A Peter Wiesli Frauenfeld Switzerland Pfaffenholzstr. 4 N/A 0 0 2'500.00 0 2500 N/A N/A Klaus Wolf Olten Switzerland Louis Giroudstr. 20 0 0 1'000.00 0 1000 OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons (Art. 275.1, 275.2 PCC) Aggregate amount attributable to transfers of value to such Recipients 564.15 2781.00 24810.00 28197.15 nicht anwendbar nicht anwendbar 42.00 Number of Recipients in aggregate disclosure nicht anwendbar nicht anwendbar 2 3 21 1 23 100% 74% 100% nicht anwendbar nicht anwendbar 56% nicht anwendbar Hôpital du Valais Sion Switzerland Av. du Grand Champsec 86 1'000.00 1000 1600.00 94557.35 0 0 0 0 96157.35 0 24 sesamtzahl der Empfänger geldwerter Leistungen pro Unterart 21 0 0 nzentualer Anteil im Verhältnis zu allen IFK-Empfängern geldwerter Leistungen pro Unterari 100% 99% % % nicht anwendbar % GGREGATE DISCLOSURE RESEARCH & DEVELOPMENT _ Fransfers of Value re Research & Development as defined (Art. 138 PCC, Art. 275.3 PCC) 5'000.00

In accordance to the Swiss Pharma-Cooperation-Codex (PCC) and the Swiss Pharma-Codex (PC) HCP = Healthcare Professional (Art. 133 PCC)
HCO = Healthcare Organisation (Art. 134 PC)

R&D = Research & Development
Reporting period includes one calendar year